BLOCK PCNSL (NHL32)
An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma
Lymphoma (non Hodgkin’s lymphoma)
The purpose of this study is to determine if a standard chemotherapy induction therapy followed by maintenance using pembrolizumab will be effective in maintaining life expectancy with minimal side effects for participants.
Key inclusion criteria
Treatment-naïve new diagnosis of PCNSL (DLBCL)
Age = greater than or equal to 18 years
ECOG = less than or equal to 3
Considered appropriate for induction CIT as per investigator
No standard contraindication to immune checkpoint inhibition
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Active autoimmune disease
Unfit for induction CIT (prohibitive organ dysfunction)
Non-B-cell lymphoma subtype
Systemic involvement with aggressive lymphoma
Unfit for induction CIT (prohibitive organ dysfunction)
Non-B-cell lymphoma subtype
Systemic involvement with aggressive lymphoma
Louise Hay
louise.hay@health.wa.gov.au
08 6383 3207
Dr. Gavin Cull
Australasian Leukaemia and Lymphoma Group
Phase 2
BLOCK PCNSL
ACTRN12619000518167